Luseogliflozin was associated with consistent glycemic and metabolic improvements across multiple systematic reviews evaluating its use in adults with T2DM. Diabetes, Metabolic Syndrome and Obesity reported an umbrella review synthesizing evidence from randomized controlled trials and observational studies.

The umbrella review included 14 systematic reviews. Literature searches were conducted in PubMed, EMBASE, and Web of Science through June 10, 2024. Study selection, data extraction, and quality assessment followed Joanna Briggs Institute and PRISMA methodology. Statistical analyses were performed using R software version 4.3.

Luseogliflozin was associated with reductions in HbA1c with a pooled mean difference of −1.784 (95% confidence interval [CI]: −3.99 to −0.431). FPG declined by −3.165 mmol/L (95% CI: −4.046 to −2.284), and PPG declined by −37.148 mg/dL (95% CI: −65.361 to −8.935). Body weight decreased by −1.322 kg (95% CI: −1.58 to −1.056). Additional improvements included reductions in TG (−13.891 mg/dL; 95% CI: −26.539 to −1.243), uric acid (−0.350 mg/dL; 95% CI: −0.524 to −0.176), and ALT (−7.345 U/L; 95% CI: −5.845 to −1.463).

Hypoglycemia risk was not significantly increased, with a pooled risk ratio of 1.305 (95% CI: 0.692 to 2.459). These findings indicate that luseogliflozin demonstrates significant glycemic and metabolic effects with a neutral hypoglycemia profile. Long-term studies are warranted to clarify its broader clinical utility and support regulatory evaluation.